 |
VasoMedical to Showcase BIOXTM Products at Southeast Asian Healthcare and Pharma Show in Kuala Lumpur, Malaysia |
April 15, 2012 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will attend and exhibit at the 16th Southeast Asian Healthcare and Pharma Show (SEACare) from April 24 to April 27, 2013 in Kuala Lumpur, Malaysia.
The Southeast Asian Healthcare and Pharma Show is an international healthcare exhibition showcasing medical devices and equipment, pharmaceuticals and medical beauty products. The international event attracts exhibitors from more than 15 countries and this year expects 5,000 to 6,000 visitors from the Southeast Asian region to attend. At this event, VasoMedical will present its BIOX line of ambulatory monitoring systems and software, as well as additional patient management products.
“As the largest healthcare event in Malaysia, SEACare is an important platform for VasoMedical to reach medical professionals from the Southeast Asian region and across the globe in order to continue spreading awareness about our company's offerings,” said Larry Liebman, vice president, sales & marketing for VasoMedical.
The Company will also showcase its BIOX brand of ECG Holter and ambulatory blood pressure monitoring products, including its fast and user-friendly customizable analysis and reporting software. BIOX Instruments, a wholly owned subsidiary of VasoMedical, was recently awarded the Excellent Trusted Enterprises Award (top-tier) by the Jiangsu Province State Food and Drug Administration (SFDA) of China.
“This meeting in Southeast Asia is well timed for us to further promote our BIOX line of products among customers in a region where we already have a strong presence for our clinically proven safe and effective EECP® Therapy products,” concluded Mr. Liebman.
VasoMedical will be located at Booth A-098-1 in the Kuala Lumpur Convention Centre.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com